baccaratbarsolaire| Watson Biotech: The company is currently working on a clinical development plan based on 9-valent HPV products

Economics 2024-04-13

Tonghuashun (300033) Financial Research Center, April 12baccaratbarsolaireSome investors asked Watson Biotech (300142)(300142). According to the company's September 2022 announcement, the company's nine-valent HPV vaccine has begun clinical phase III in 2022. Market rumors that the Phase III clinical trial of the company's nine-valent HPV vaccine to compare the immunogenicity of the company's nine-valent HPV vaccine with similar vaccines has not yet opened. What is the actual clinical progress and relevant data of the company's nine-valent HPV vaccine in the phase III clinical trial of the main efficacy?

The company replied, Dear investors, hellobaccaratbarsolaire! The company is currently maintaining close communication with CDE based on the clinical development plan of 9-valent HPV products, and actively striving to conduct clinical research on protective effectiveness with optimal strategies. Thank you!

baccaratbarsolaire| Watson Biotech: The company is currently working on a clinical development plan based on 9-valent HPV products

Comments
Copyright Your WebSite.Some Rights Reserved.
Powered By Z-BlogPHP.